Funding round
Nimbus Therapeutics Growth
Reported as "Growth Equity"
Nimbus Therapeutics, which works in precision small molecule drug discovery in Boston, raised $210M in a Growth round announced on 6 Sep 2023, led by GV, SR One and Atlas Venture. 10 firms took part, 9 of them already investors. It is Nimbus Therapeutics' seventh venture round on record; the one before was a Growth in Sep 2022.
$210M
Amount raised
Not disclosed
Post-money valuation
10
Investors
3 leads
Valuation
What this round says about the price
Nimbus Therapeutics did not disclose a valuation in this round. It came 12 months after Nimbus Therapeutics' Growth. It is 37% of the $569M Nimbus Therapeutics has raised in the venture rounds on record. No later venture round is on record for Nimbus Therapeutics.
Nimbus Therapeutics' funding rounds
Nimbus Therapeutics has 7 venture rounds on record. This one is highlighted.
- Seed 1 Mar 2011 $1.5M
- Series A 28 Jun 2011, led by Atlas Venture, SR One and Lilly Ventures $24M
- Series B 18 Mar 2015, led by Pfizer Venture Investments and Lightstone Ventures $43M
- Growth 14 Oct 2020, led by RA Capital $60M
- Growth 13 Jul 2021, led by BVF Partners L.P. $105M
- Growth 12 Sep 2022, led by Bain Capital Life Sciences and SV Health Investors $125M
- Growth this round 6 Sep 2023, led by GV, SR One and Atlas Venture $210M
Investors
Who put money in
GV, SR One and Atlas Venture led the round with 7 other firms. SR One, Atlas Venture, Bain Capital Life Sciences and BVF Partners L.P. and 5 more had backed Nimbus Therapeutics before.
Lead investors
- GV backs 428 venture-backed companies new investor
- backs 22 venture-backed companies existing investor
- backs 43 venture-backed companies existing investor
Also in the round
- Bain Capital Life Sciences existing investor
- BVF Partners L.P. existing investor
- Gates Frontier existing investor
- backs 25 venture-backed companies existing investor
- Pfizer Ventures existing investor
- backs 109 venture-backed companies existing investor
- backs 46 venture-backed companies existing investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
29 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $50M, and this round was 4.2 times the median. The closest in time, other companies' Growth rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 15 Sep 2023 | $350M | not disclosed | BlackRock Capital Investment Advisors, LLC and PNC Bank, National Association |
| Pharmaceutical Products | 3 Jul 2023 | $152M | not disclosed | not named |
| Pharmaceutical Products | 26 Jul 2023 | $36M | not disclosed | Kineticos |
| Pharmaceutical Products | 2 Nov 2023 | $19M | not disclosed | Ampersand Capital Partners |
| ITM Radiopharma Pharmaceutical Products | 1 Jan 2024 | $205M | not disclosed | Temasek |
| Pharmaceutical Products | 3 Jan 2024 | $60M | not disclosed | The Column Group |
| Pharmaceutical Products | 19 Jan 2024 | $26M | not disclosed | not named |
| Pharmaceutical Products | 20 Apr 2023 | $315M | not disclosed | CBC Group and Mubadala |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did Nimbus Therapeutics raise in its Growth round?
Nimbus Therapeutics raised $210M in its Growth round, announced in Sep 2023.
Who led Nimbus Therapeutics' Growth round?
GV, SR One and Atlas Venture led it, with Bain Capital Life Sciences, BVF Partners L.P., Gates Frontier, Lightstone Ventures and Pfizer Ventures and 2 more.
What was Nimbus Therapeutics' valuation at the Growth round?
It was not disclosed.
How does it compare with other Growth rounds in Pharmaceutical Products?
29 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $50M, and this round was 4.2 times the median.